Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study
Authors:
- Hermann HallerHHHermann Haller
- Gian C VibertiGVGian C Viberti
- Albert MimranAMAlbert Mimran
- Giuseppe RemuzziGiuseppe Remuzzi
- Antonius J RabelinkARAntonius J Rabelink
- Eberhard RitzEREberhard Ritz
- Lars C RumpLRLars C Rump
- Luis M RuilopeLRLuis M Ruilope
- Shigehiro KatayamaSKShigehiro Katayama
- Sadayoshi ItoSadayoshi Ito
- Joseph L IzzoJIJoseph L Izzo
- Andrzej JanuszewiczAJAndrzej Januszewicz
- 1 February 2006
- journal article
- research article
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 24 (2) , 403-408
Abstract
Diabetic nephropathy has developed into a worldwide epidemic and is responsible for the majority of end-stage renal disease in most countries. Antihypertensive treatment slows the progression of the disease. In addition, blockade of the renin–angiotensin system reduces the degree of albuminuria and angiotensin II receptor blockers (ARBs) have been shown to delay the progression from microalbuminuria to overt proteinuria in patients with diabetes. However, few studies have examined whether the initial stage of diabetic nephropathy (i.e. the development of microalbuminuria) in patients with type 2 diabetes can be slowed or prevented by ARB treatment. The Randomised Olmesartan And Diabetes MicroAlbuminuria Prevention (ROADMAP) study is a placebo-controlled, multicentre, double-blind, parallel group study investigating the effect of the ARB, olmesartan medoxomil, on the incidence of microalbuminuria. A total of 4400 type 2 diabetes patients with normoalbuminuria will be randomized to treatment with 40 mg of olmesartan medoxomil once daily or placebo. Goal blood pressure will be 130/80 mmHg. The primary endpoint of the study is the occurrence of microalbuminuria. In ROADMAP, we will also assess as secondary endpoints the effects of olmesartan on fatal and non-fatal cardiovascular events in patients with diabetes. In addition, within subgroups of the ROADMAP patients, the effects of olmesartan on retinopathy and other microvascular circulations will be analysed. The study is expected to last a median of 5 years. The ROADMAP study will answer the question whether an ARB can prevent or delay the onset of microalbuminuria and whether this translates into protection against cardiovascular events and renal disease.Keywords
This publication has 33 references indexed in Scilit:
- Antihypertensive Agents for Primary Prevention of Diabetic NephropathyJournal of the American Society of Nephrology, 2005
- Chronic Angiotensin II Receptor Blockade Reduces (Intra)Renal Vascular Resistance in Patients with Type 2 DiabetesJournal of the American Society of Nephrology, 2005
- Angiotensin II receptor blocker inhibits p27Kip1 expression in glucose-stimulated podocytes and in diabetic glomeruliKidney International, 2005
- Angiotensin receptor blockers and myocardial infarctionBMJ, 2004
- Antiinflammatory Effects of Angiotensin II Subtype 1 Receptor Blockade in Hypertensive Patients With MicroinflammationCirculation, 2004
- Microalbuminuria and all-cause mortality in 2,089 apparently healthy individuals: a 4.4-year follow-up study. The Nord-Trøndelag Health Study (HUNT), NorwayAmerican Journal of Kidney Diseases, 2003
- Development of Renal Disease in People at High Cardiovascular RiskJournal of the American Society of Nephrology, 2003
- Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64)Kidney International, 2003
- Olmesartan MedoxomilDrugs, 2002
- Role of angiotensin II in diabetic nephropathyKidney International, 2000